192 related articles for article (PubMed ID: 12460033)
1. Anemia treatment in the pre-ESRD period and associated mortality in elderly patients.
Xue JL; St Peter WL; Ebben JP; Everson SE; Collins AJ
Am J Kidney Dis; 2002 Dec; 40(6):1153-61. PubMed ID: 12460033
[TBL] [Abstract][Full Text] [Related]
2. Anemia management and association of race with mortality and hospitalization in a large not-for-profit dialysis organization.
Servilla KS; Singh AK; Hunt WC; Harford AM; Miskulin D; Meyer KB; Bedrick EJ; Rohrscheib MR; Tzamaloukas AH; Johnson HK; Zager PG
Am J Kidney Dis; 2009 Sep; 54(3):498-510. PubMed ID: 19628315
[TBL] [Abstract][Full Text] [Related]
3. Epoetin alfa use in patients with ESRD: an analysis of recent US prescribing patterns and hemoglobin outcomes.
Collins AJ; Brenner RM; Ofman JJ; Chi EM; Stuccio-White N; Krishnan M; Solid C; Ofsthun NJ; Lazarus JM
Am J Kidney Dis; 2005 Sep; 46(3):481-8. PubMed ID: 16129210
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
Besarab A; Salifu MO; Lunde NM; Bansal V; Fishbane S; Dougherty FC; Beyer U;
Clin Ther; 2007 Apr; 29(4):626-39. PubMed ID: 17617286
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.
Wizemann V; Rutkowski B; Baldamus C; Scigalla P; Koytchev R;
Curr Med Res Opin; 2008 Mar; 24(3):625-37. PubMed ID: 18208642
[TBL] [Abstract][Full Text] [Related]
6. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin.
Besarab A; Bolton WK; Browne JK; Egrie JC; Nissenson AR; Okamoto DM; Schwab SJ; Goodkin DA
N Engl J Med; 1998 Aug; 339(9):584-90. PubMed ID: 9718377
[TBL] [Abstract][Full Text] [Related]
7. The effect of a change in epoetin alfa reimbursement policy on anemia outcomes in hemodialysis patients.
Berns JS; Fishbane S; Elzein H; Lynn RI; Deoreo PB; Tharpe DL; Meisels IS
Hemodial Int; 2005 Jul; 9(3):255-63. PubMed ID: 16191075
[TBL] [Abstract][Full Text] [Related]
8. Association between hematocrit level and mortality in hemodialysis patients. Case study of the anemic patient.
Collins A; Ellefson J
Nephrol Nurs J; 2000 Apr; 27(2):233-6. PubMed ID: 11111551
[TBL] [Abstract][Full Text] [Related]
9. Anemia management and treatment response in patients on hemodialysis: the MAR study.
Portolés J; López-Gómez JM; Aljama P
J Nephrol; 2006; 19(3):352-60. PubMed ID: 16874697
[TBL] [Abstract][Full Text] [Related]
10. Anaemia management prior to dialysis: cardiovascular and cost-benefit observations.
Collins AJ
Nephrol Dial Transplant; 2003 Jun; 18 Suppl 2():ii2-6. PubMed ID: 12819293
[TBL] [Abstract][Full Text] [Related]
11. Extended epoetin alfa dosing in chronic kidney disease patients: a retrospective review.
Germain M; Ram CV; Bhaduri S; Tang KL; Klausner M; Curzi M
Nephrol Dial Transplant; 2005 Oct; 20(10):2146-52. PubMed ID: 15985516
[TBL] [Abstract][Full Text] [Related]
12. Is early treatment of anaemia with epoetin-alpha beneficial to pre-dialysis chronic kidney disease patients? Results of a multicentre, open-label, prospective, randomized, comparative group trial.
Macdougall IC; Temple RM; Kwan JT
Nephrol Dial Transplant; 2007 Mar; 22(3):784-93. PubMed ID: 16968726
[TBL] [Abstract][Full Text] [Related]
13. Factors affecting survival in advanced chronic kidney disease patients who choose not to receive dialysis.
Wong CF; McCarthy M; Howse ML; Williams PS
Ren Fail; 2007; 29(6):653-9. PubMed ID: 17763158
[TBL] [Abstract][Full Text] [Related]
14. A comparison between once-weekly and twice- or thrice-weekly subcutaneous injection of epoetin alfa: results from a randomized controlled multicentre study.
Lee YK; Kim SG; Seo JW; Oh JE; Yoon JW; Koo JR; Kim HJ; Noh JW
Nephrol Dial Transplant; 2008 Oct; 23(10):3240-6. PubMed ID: 18469158
[TBL] [Abstract][Full Text] [Related]
15. Hematocrit was not validated as a surrogate end point for survival among epoetin-treated hemodialysis patients.
Cotter DJ; Stefanik K; Zhang Y; Thamer M; Scharfstein D; Kaufman J
J Clin Epidemiol; 2004 Oct; 57(10):1086-95. PubMed ID: 15528060
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of epoetin alfa therapy for anemia of end-stage renal disease.
Moran LJ; Carey P; Johnson CA
Am J Hosp Pharm; 1992 Jun; 49(6):1451-4. PubMed ID: 1529988
[TBL] [Abstract][Full Text] [Related]
17. The new rHuEPO alpha (epotin) in the management of anemia of end-stage renal disease in patients on maintenance hemodialysis.
Abbas EE; Afioni N; Al Wakeel J; Bakr MA; Dham R; Donia A; Droubi N; Khidir E; Mathew CM; Mitwali AH; Naga S; Pingle A; Rashed A; Roshdy A; Shaheen F; Shaibani B; Shaibani FM; Shaker DS; Sheiban A; Solieman M
Transplant Proc; 2004; 36(6):1805-11. PubMed ID: 15350482
[TBL] [Abstract][Full Text] [Related]
18. Impact of timing of nephrology referral and pre-ESRD care on mortality risk among new ESRD patients in the United States.
Stack AG
Am J Kidney Dis; 2003 Feb; 41(2):310-8. PubMed ID: 12552491
[TBL] [Abstract][Full Text] [Related]
19. Greater Epoetin alfa (EPO) doses and short-term mortality risk among hemodialysis patients with hemoglobin levels less than 11 g/dL.
Bradbury BD; Do TP; Winkelmayer WC; Critchlow CW; Brookhart MA
Pharmacoepidemiol Drug Saf; 2009 Oct; 18(10):932-40. PubMed ID: 19572312
[TBL] [Abstract][Full Text] [Related]
20. 12-week clinical effects of erythropoietin espogen in end stage renal patients undergoing hemodialysis.
Thitiarchakul S; Tasanarong A
J Med Assoc Thai; 2007 Apr; 90(4):636-42. PubMed ID: 17487116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]